One-year clinical remission with tezepelumab in severe asthma: TERESA single-arm prospective study
Journal of Allergy and Clinical Immunology · 2026
DOI: 10.1016/j.jaci.2026.05.006 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026. Verfasst von Keiko Kan-O und 49 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Respiratory Medicine, Tokyo…. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca KK.
Abstract (Originalsprache)
BACKGROUND: Clinical remission has emerged as an ambitious therapeutic goal in severe asthma, shifting emphasis from symptomatic relief to long-term disease modification. Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin, has demonstrated broad-spectrum anti-inflammatory activity. However, prospective data assessing clinical remission with tezepelumab, especially in biologic-experienced patients, remain limited. OBJECTIVE: The Tezepelumab-induced Clinical Remission in Severe Asthma (TERESA) study is a multicenter, prospective, single-arm, investigator-initiated phase 4 study evaluating clinical remission at week 52 in patients with uncontrolled severe asthma receiving tezepelumab every 4 weeks. METHODS: Clinical remission was defined as the absence of asthma exacerbations, discontinuation of maintenance oral corticosteroids, an Asthma Control Questionnaire 6 score of ≤1.5, and stabilized lung function. Secondary end points included complete remission (clinical remission plus type 2 biomarker negativity). RESULTS: Among 107 patients enrolled (including 50 biologic-experienced patients), 34.6% (95% confidence interval, 26.2, 44.0) obtained clinical remission at week 52. Complete remission was observed in 9.3%. Biologic-naive patients demonstrated higher remission rates than biologic-experienced patients (47.4% vs 20.0%, respectively). Multivariable logistic regression identified absence of previous biologic receipt (adjusted odds ratio, 3.61; 95% confidence interval, 1.29, 10.15) and baseline blood eosinophil count ≥ 300 cells/μL (adjusted odds ratio, 5.10; 95% confidence interval, 1.23, 21.18) as independent predictors of clinical remission. CONCLUSION: In this single-arm study with 1 year's follow-up, tezepelumab resulted in clinical remission in approximately one third of patients with severe asthma, with a favorable safety profile. Higher baseline eosinophil count and biologic-naive status were key predictors of remission, underscoring tezepelumab's potential to obtain comprehensive disease control in appropriately selected patients. CLINICAL TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCTs071230026).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan. Electronic address: kano.ke…
- Department of Statistics and Data Center, Clinical Research Support Center Kyushu, Fukuoka, Japan.
- Department of Pulmonary Medicine, National Hospital Organization Okinawa Hospital, Okinawa, Japan.
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
- Department of Medicine, Division of Respiratory Medicine and Allergology, Showa Medical University School of Medicine, Tokyo, Japan.
- Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Förderung
- AstraZeneca KK
Zitieren
APA
Kan-O, K., Watanabe, H., Chibana, K., Suzukawa, M., Tanaka, A., Masaki, K., Ohta, S., Kabata, H., Asano, K., Ito, R., Inoue, H., Nakano, T., Kanda, H., Yamashita, T., Obase, Y., Kobayashi, K., Sugimoto, N., Ito, Y., Ogata, H., …, & Okamoto, I. (2026). One-year clinical remission with tezepelumab in severe asthma: TERESA single-arm prospective study. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2026.05.006
Vancouver
Kan-O K, Watanabe H, Chibana K, Suzukawa M, Tanaka A, Masaki K, et al. One-year clinical remission with tezepelumab in severe asthma: TERESA single-arm prospective study. Journal of Allergy and Clinical Immunology. 2026. doi:10.1016/j.jaci.2026.05.006
BibTeX
@article{KanO2026,
author = {Kan-O, Keiko and Watanabe, Hiroko and Chibana, Kenji and Suzukawa, Maho and Tanaka, Akihiko and Masaki, Katsunori and Ohta, Shin and Kabata, Hiroki and Asano, Koichiro and Ito, Reiko and Inoue, Hiromasa and Nakano, Takako and Kanda, Hideki and Yamashita, Takafumi and Obase, Yasushi and Kobayashi, Konomi and Sugimoto, Naoya and Ito, Yoko and Ogata, Hiroaki and Takagi, Koichi and Ohshima, Nobuharu and Kinoshita, Takashi and Tashiro, Hiroki and Takahashi, Koichiro and Oishi, Keiji and Hirano, Tsunahiko and Sakakibara, Hideki and Sennari, Konomi and Sugimoto, Yukihiro and Shiroyama, Takayuki and Fukahori, Susumu and Oguma, Tsuyoshi and Tomomatsu, Katsuyoshi and Shimada, Sho and Kondo, Mitsuko and Akaba, Tomohiro and Yoshimi, Michihiro and Moriuchi, Yuki and Ujike, Mari and Mitsui, Miho and Shimizu, Kaoruko and Shindo, Yuichiro and Takasawa, Seiko and Wakahara, Keiko and Uno, Tomoki and Miyata, Jun and Ishida, Akane and Tsuji, Mayoko and Shimada, Akikazu and Okamoto, Isamu},
title = {One-year clinical remission with tezepelumab in severe asthma: TERESA single-arm prospective study},
journal = {Journal of Allergy and Clinical Immunology},
year = {2026},
doi = {10.1016/j.jaci.2026.05.006}
}
EUVIMED